Actinogen Medical Completes AU$8.1 Million Placement, Launches AU$3 Million Share Purchase Plan; Shares Fall 9%

MT Newswires Live09-18

Actinogen Medical (ASX:ACW) completed an AU$8.1 million placement and launched a AU$3 million share purchase plan to advance its XanaMIA Alzheimer's trial, according to a Wednesday filing with the Australian bourse.

The placement comprised roughly 270 million new shares issued at AU$0.03 each, with three options granted for every four shares. The options are exercisable at AU$0.05 and will expire on Sept. 30, 2027.

Chief Executive Officer Steven Gourlay subscribed for AU$1 million in the placement, while other directors subscribed for a total of AU$130,000, subject to shareholder approval.

Meanwhile, the share purchase plan offers a maximum of 100 million shares and 75 million new options on the same terms as the placement, the filing stated.

The biotechnology company's shares were down nearly 9% in recent Wednesday. trade.

Price (AUD): $0.03, Change: $-0.0030, Percent Change: -8.57%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468322062?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-18 14:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2468322062","market":"sg","top_or_hot":-1,"title":"Actinogen Medical Completes AU$8.1 Million Placement, Launches AU$3 Million Share Purchase Plan; Shares Fall 9%","media":"MT Newswires Live","content":"<html><body><p> Actinogen Medical (ASX:ACW) completed an AU$8.1 million placement and launched a AU$3 million share purchase plan to advance its XanaMIA Alzheimer's trial, according to a Wednesday filing with the Australian bourse.</p><p>The placement comprised roughly 270 million new shares issued at AU$0.03 each, with three options granted for every four shares. The options are exercisable at AU$0.05 and will expire on Sept. 30, 2027.</p><p>Chief Executive Officer Steven Gourlay subscribed for AU$1 million in the placement, while other directors subscribed for a total of AU$130,000, subject to shareholder approval.</p><p>Meanwhile, the share purchase plan offers a maximum of 100 million shares and 75 million new options on the same terms as the placement, the filing stated.</p><p>The biotechnology company's shares were down nearly 9% in recent Wednesday. trade.</p><p>Price (AUD): $0.03, Change: $-0.0030, Percent Change: -8.57%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinogen Medical Completes AU$8.1 Million Placement, Launches AU$3 Million Share Purchase Plan; Shares Fall 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinogen Medical Completes AU$8.1 Million Placement, Launches AU$3 Million Share Purchase Plan; Shares Fall 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-18 14:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Actinogen Medical (ASX:ACW) completed an AU$8.1 million placement and launched a AU$3 million share purchase plan to advance its XanaMIA Alzheimer's trial, according to a Wednesday filing with the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2468322062","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468322062","pubTimestamp":1726639615,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Actinogen Medical  completed an AU$8.1 million placement and launched a AU$3 million share purchase plan to advance its XanaMIA Alzheimer's trial, according to a Wednesday filing with the Australian bourse.The placement comprised roughly 270 million new shares issued at AU$0.03 each, with three options granted for every four shares. The options are exercisable at AU$0.05 and will expire on Sept. 30, 2027.Chief Executive Officer Steven Gourlay subscribed for AU$1 million in the placement, while other directors subscribed for a total of AU$130,000, subject to shareholder approval.Meanwhile, the share purchase plan offers a maximum of 100 million shares and 75 million new options on the same terms as the placement, the filing stated.The biotechnology company's shares were down nearly 9% in recent Wednesday. trade.Price : $0.03, Change: $-0.0030, Percent Change: -8.57%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7067":"生物科技","BK4125":"广播","AUD":"Audacy Inc.","ACW.AU":"ACTINOGEN MEDICAL LTD"},"translate_title":"Actinogen Medical完成810万澳元配售，启动300万澳元购股计划；股价下跌9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"ACW.AU":0.9},"content_text":"Actinogen Medical (ASX:ACW) completed an AU$8.1 million placement and launched a AU$3 million share purchase plan to advance its XanaMIA Alzheimer's trial, according to a Wednesday filing with the Australian bourse.The placement comprised roughly 270 million new shares issued at AU$0.03 each, with three options granted for every four shares. The options are exercisable at AU$0.05 and will expire on Sept. 30, 2027.Chief Executive Officer Steven Gourlay subscribed for AU$1 million in the placement, while other directors subscribed for a total of AU$130,000, subject to shareholder approval.Meanwhile, the share purchase plan offers a maximum of 100 million shares and 75 million new options on the same terms as the placement, the filing stated.The biotechnology company's shares were down nearly 9% in recent Wednesday. trade.Price (AUD): $0.03, Change: $-0.0030, Percent Change: -8.57%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468322062"}